April 12, 2018June 22, 2018

FDA Grants Priority Review to Duvelisib for Two Lymphoma Types

News

The U.S. Food and Drug Administration (FDA) will review an application requesting duvelisib’s full approval for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for ... Read more

January 2, 2018

Verastem to Seek FDA Approval for Duvelisib to Treat SLL and CLL After Consistently Positive Trial Results

News

Verastem‘s duvelisib significantly delays disease progression or death in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to Phase 3 trial results. The trial, called ... Read more